JUN 05, 2019 5:01 PM PDT

Additional drug in hormone therapy for breast cancer extends women's lives

The findings from a new clinical trial were presented this week at the American Society of Clinical Oncology annual meeting in Chicago. The trial showed that the addition of a drug called Kisqali (ribociclib) to standard hormone therapy has the capability of lengthening the lives of younger women with advanced breast cancer. The trial’s findings will be published in the New England Journal of Medicine.

The trial was led by Dr. Debu Tripathy, chair of the breast medical oncology department at M.D. Anderson Cancer Center in Houston. All of the women participating in the trial received standard hormonal therapy, in addition to a medication that turns off the ovaries' production of estrogen. Dr. Tripathy’s team also gave half of the women Kisqali and half a placebo.

Kisqali is taken as a tablet and is in a class of drugs called CDK4/6 inhibitors; it functions by blocking two proteins that help cancer cells grow and divide.

The trial found that on average, the women who received Kisqali lived six months longer than women in the control group. After 3.5 years, 70% of patients given hormone therapy plus Kisqali were still alive, compared to 46% of those given hormone therapy alone.

"In reality, what this means is if we get a confirmation from the bigger trial, then this could well lead to a change in the standard of care across the world,” said Dr. Rob Jones, trial co-leader and a consultant in oncology. "When you're given a diagnosis of cancer that is incurable, any extension of life is incredibly important," he added. "We've talked about averages but there are plenty of examples in the trial of patients who have lived for two or three years without their disease yet progressing."

Kisqali could extend the lives of women with advanced breast cancer. Photo: Pixabay

The researchers hope that this trial will provide enough evidence to make significant changes in the standard of care offered to premenopausal women with advanced breast cancer. They hope it will extend worldwide.

Sources: BBC, CBS News

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 12, 2021
Drug Discovery & Development
Drug Starves Melanoma Tumors
MAR 12, 2021
Drug Starves Melanoma Tumors
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a drug candidate that blocks the uptake ...
MAR 29, 2021
Cancer
Modeling metastasis
MAR 29, 2021
Modeling metastasis
Novel research published in Genome Biology investigates the cellular mechanisms at work during cancer metastasis using n ...
APR 04, 2021
Drug Discovery & Development
Ion-Pump for Chemotherapy
APR 04, 2021
Ion-Pump for Chemotherapy
Patients of malignant brain tumors experience recurrences even after subsequent treatments. To address this issue, scien ...
APR 19, 2021
Health & Medicine
Using Artificial Intelligence to Understand the Language of Cancer and Alzheimer's Disease
APR 19, 2021
Using Artificial Intelligence to Understand the Language of Cancer and Alzheimer's Disease
Cancer and Alzheimer’s disease are life-changing, and there is still much we don’t understand about what cau ...
MAY 28, 2021
Cancer
Does your birth control increase your risk of breast cancer?
MAY 28, 2021
Does your birth control increase your risk of breast cancer?
A study published recently in EMBO Molecular Medicine considers the biological impacts of progestins from hormonal contr ...
JUN 06, 2021
Cancer
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
JUN 06, 2021
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
The most recent results from the CODEBREAK 100 phase 2 clinical trial support the use of the drug sotorasib to reduce tu ...
Loading Comments...